New combo therapy aims to shrink melanoma before surgery
NCT ID NCT04139902
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) before their operation. The main goal is to see how many patients have most of their tumor killed by the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UPMC Hillman Cancer Center Washington
Washington, Pennsylvania, 15301, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.